Reinventing medicines

Our investigational medicines can offer simple new ways for patients and caregivers to use proven and trusted molecules. Our pipeline includes several investigational treatments for patients facing challenges in using their prescribed medication. Looking ahead, we see even greater potential for PharmFilm® technology to improve patient treatment and are working to deliver simplified, complex molecules, proteins, and peptides on oral film with newer prodrugs and technologies.

Product Pipeline

Click for details

Program

Molecule

Targeted Indication

Formulation Pre-Clinical/Proof of Concept Phase 1 Phase 2 Phase 3 Filed Marketed

CNS Programs

LIBERVANT^TM*
(EX US Partner: Pharmanovia)

diazepam^†

Breakthrough Seizures / Cluster Seizures

Tentative Approval Granted

Tentative approval granted; expected launch in 2027

In development as an oral rescue therapy for breakthrough seizures / cluster seizures

Complex Molecule Programs

ANAPHYLM™*

epinephrine^†

Anaphylaxis

Clinical

Received conditional proprietary approval from FDA

Emergency treatment of allergic reactions including anaphylaxis

AQST-108

epinephrine^†

(Alternative Indications)

Clinical

In development as a treatment for anaphylaxis, severe allergy

Licensed programs

SUBOXONE®
(Partner: Indivior)

buprenorphine / naloxone

FDA Approved 2010

For more information, visit www.suboxone.com or download the Prescribing Information

ZUPLENZ®
(Ondif in Brazil)

ondansetron

FDA Approved 2010

For more information, download the Prescribing Information

SYMPAZAN®
(Partner: Otter Pharmaceuticals)

clobazam

FDA Approved 2018

For more information, visit www.sympazan.com or download the Prescribing Information

EXSERVAN^TM
(EU Partner: Zambon;
US Partner: Mitsubishi Tanabe;
Chinese Partner: Haisco)

riluzole

FDA Approved 2019

For more information, visit www.exservan.com or download the Prescribing Information

KYNMOBI^TM
(Partner: Sunovion)

apomorphine

FDA Approved 2020

For more information, visit www.kynmobi.com or download the Prescribing Information

AZSTARYS®
(Partner: Corium)

serdexmethylphenidate and dexmethylphenidate

FDA Approved 2021

For more information, visit https://www.azstarys-pro.com or download the Prescribing Information

Essential information for the investment community

Keep current with Aquestive

Aquestive sponsored clinical trials

Learn More

Clinical trial news and other updates

Visit the newsroom

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.
Comments
This field is for validation purposes and should be left unchanged.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Full name*
Email address*
Street Address*
City*
Zip Code*
Phone number*
Tell us how we can help your brand
Send me a kit
- Send me a PharmFilm® demonstration kit
I am interested in:
- Commercializing an existing product
- Commercializing a product in development
- Investment opportunities
To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive marketing updates regarding products and services from Aquestive Therapeutics.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
In what clinical trial are you interested?
To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

First Name*
Last Name*
Email Address*
Phone Number*
Role within the Epilepsy Community*
- Patient/Caregiver
- HCP
- Other
Tell us how we can assist you
- By providing my contact information, I agree that Aquestive Therapeutics (“Aquestive”) can use such information for its marketing database and that Aquestive and its agents may contact me by mail or email to provide information about Aquestive or its products or services. I understand that my contact information will not be sold to third parties, other than in the event Aquestive or its affiliates are sold. I understand that I have the right to opt-out of the database and have my information removed from the database at any time. Instructions on how to be removed from the database will be included in any future communications sent to me by Aquestive. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing lgsart@aquestive.com.

Pipeline

An expanding portfolio

Reinventing medicines

Product Pipeline

In development as an oral rescue therapy for breakthrough seizures / cluster seizures

Emergency treatment of allergic reactions including anaphylaxis

In development as a treatment for anaphylaxis, severe allergy

Essential information for the investment community

Aquestive sponsored clinical trials

Clinical trial news and other updates

Please complete this form:

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Please complete this form:

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

Please complete our short form to speak with a business development specialist.